Table 4. SGX393-imatinib combination mutagenesis study

		Total wells (sequenced clones)	Mutation recovered	Number of occurences	Frequency (%)	Mutations recovered (by residue)	Frequency (by residue) (%)
SGX393 + imatinib combinations							
[SGX393]	[imatinib]						
240nM	2000nM	96 (n=46)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248R	2	4.3	248	6.5
			L248V	1	2.2		
			G250E	12	26.1	250	26.1
			Q252H	3	6.5	252	6.5
			Y253C	1	2.2		
			Y253F	4	8.7	253	50.0
			Y253H	14	30.4		
			Y253N	4	8.7		
			E255K	1	2.2	255	8.7
			E255V	3	6.5		
			F317L	1	2.2	317	2.2
240nM	4000nM	96 (n=9)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248Q	1	11.1	248	11.1
			G250E	4	44.4	250	44.4
			Y253F	1	11.1	253	33
			Y253H	2	22.2		
			E255K	1	11.1	255	11.1
480nM	2000nM	288 (n=76)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248K	1	1.3	248	10.5
			L248Q	3	3.9		
			L248R	4	5.3		
			G250A	1	1.3	250	25.0
			G250E	18	23.7		
			Q252H	5	6.6	252	6.6
			Y253F	13	17.1	253	38.2
			Y253H	16	21.1		
			E255V	14	18.4	255	18.4
			F317L	1	1.3	317	1.3
480nM	4000nM	288 (n=42)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248R	6	14.3	248	14.3
			G250E	10	23.8	250	23.8
			Q252H	2	4.8	252	4.8
			Y253F	8	19.0	253	33.3
			Y253H	6	14.3		
			E255V	9	21.4	255	21.4
			F317I	1	2.4	317	2.4
960nM	2000nM	288 (n=27)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248K	1	3.7	248	22.2
			L248R	5	18.5		
			G250E	4	14.8	250	14.8
			Y253F	9	33.3	253	33.3
			E255V	8	29.6	255	29.6
960nM	4000nM	288 (n=19)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248K	2	10.5	248	26.3
			L248R	3	15.8		
			G250E	1	5.3	250	5.3
			Q252H	1	5.3	252	5.3
			Y253F	4	21.1	253	21.1
			E255V	8	42.1	255	42.1
1920nM	2000nM	288 (n=6)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248K	1	16.7	248	16.7
			E255V	5	83.3	255	83.3
1920nM	4000nM	288 (n=8)	Native Bcr-Abl	0	0.0	Native Bcr-Abl	0.0
			L248R	4	50.0	248	50.0
			E255V	4	50.0	255	50.0